7 results about "Glatiramer acetate" patented technology

The present invention provides an improved process for preparing microparticles comprising glatiramer acetate having low levels of residual organic solvent, in particular dichloromethane. The microparticles are incorporated into long-acting parenteral pharmaceutical compositions in a depot form, suitable for subcutaneous or intramuscular implantation or injection and useful for the treatment of multiple sclerosis.

The present invention provides compositions and methods of using them for treating or ameliorating multiple sclerosis (MS) by administering a formulation comprising 40 mg of glatiramer acetate intramuscularly to the MS patient.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and contin- ued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).

The present invention provides long-acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long-acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in a depot form suitable for administration to a medically acceptable site in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

The present disclosure relates to methods for treating cancer / inhibiting tumor growth in a patient in need thereof comprising administering to the patient an effective amount of Glatiramer acetate (GA) and an effective amount of an immune checkpoint inhibitor.